The evolution of iron chelators for the treatment of iron overload disease and cancer

DS Kalinowski, DR Richardson - Pharmacological reviews, 2005 - ASPET
The evolution of iron chelators from a range of primordial siderophores and aromatic
heterocyclic ligands has lead to the formation of a new generation of potent and efficient iron …

Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come

P Yingchoncharoen, DS Kalinowski… - Pharmacological …, 2016 - ASPET
Cancer is a leading cause of death in many countries around the world. However, the efficacy
of current standard treatments for a variety of cancers is suboptimal. First, most cancer …

[HTML][HTML] Unraveling the mysteries of serum albumin—more than just a serum protein

AM Merlot, DS Kalinowski, DR Richardson - Frontiers in physiology, 2014 - frontiersin.org
Serum albumin is a multi-functional protein that is able to bind and transport numerous
endogenous and exogenous compounds. The development of albumin drug carriers is gaining …

Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors

Y Yu, DS Kalinowski, Z Kovacevic… - Journal of medicinal …, 2009 - ACS Publications
The chemical and biological effects of thiosemicarbazones have received considerable
interest from medicinal chemists for many years. This is attributed to, first, their wide …

Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity

…, DB Lovejoy, D Senaratne, DS Kalinowski… - Journal of medicinal …, 2006 - ACS Publications
There has been much interest in the development of iron (Fe) chelators for the treatment of
cancer. We developed a series of di-2-pyridyl ketone thiosemicarbazone (HDpT) ligands …

[HTML][HTML] Cellular iron uptake, trafficking and metabolism: Key molecules and mechanisms and their roles in disease

…, DH Bae, PJ Jansson, S Sahni, DS Kalinowski… - … et Biophysica Acta (BBA …, 2015 - Elsevier
Iron is a crucial transition metal for virtually all life. Two major destinations of iron within
mammalian cells are the cytosolic iron-storage protein, ferritin, and mitochondria. In mitochondria…

Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents

DR Richardson, DS Kalinowski, S Lau… - … et Biophysica Acta (BBA …, 2009 - Elsevier
Cancer contributes to 50% of deaths worldwide and new anti-tumour therapeutics with novel
mechanisms of actions are essential to develop. Metabolic inhibitors represent an important …

Design, synthesis, and characterization of novel iron chelators: Structure− activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3 …

DS Kalinowski, Y Yu, PC Sharpe, M Islam… - Journal of medicinal …, 2007 - ACS Publications
Previously, we demonstrated that the potent antiproliferative activity of the di-2-pyridylketone
thiosemicarbazone (DpT) series of Fe chelators was due to their ability to induce Fe …

Chelators at the cancer coalface: desferrioxamine to Triapine and beyond

Y Yu, J Wong, DB Lovejoy, DS Kalinowski… - Clinical Cancer …, 2006 - AACR
The importance of iron and copper in cancer biology has been well established. Iron plays a
fundamental role in cellular proliferation and copper has been shown to be a significant …

2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor …

DR Richardson, DS Kalinowski… - Journal of medicinal …, 2009 - ACS Publications
Through systematic structure−activity studies of the 2-benzoylpyridine thiosemicarbazone (HBpT),
2-(3-nitrobenzoyl)pyridine thiosemicarbazone (HNBpT) and dipyridylketone …